A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

Mrs. Rao, a health-conscious 55-year-old, was diagnosed with a large ovarian mass after experiencing persistent abdominal ...

In just a few weeks, you will have a special opportunity to rediscover downtown La Grange and support a good cause.According to the American Cancer Society, more than 270,000 women across the United ...

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...

Mural Oncology’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Researchers found that Black and Native American patients were 23% less likely to have high levels of CA-125 when diagnosed ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

Nearly half of women diagnosed with ovarian cancer are not receiving the genetic testing that could help guide treatment and improve outcomes, according to a new analysis from Ovarian Cancer Research ...

In a study on ovarian cancer cells, researchers from Karolinska Institutet demonstrate how the tumor environment influences ...

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025.